CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma

Juan Su; Tianyuan Gao; Minghao Jiang; Lisha Wu; Weiqi Zeng; Shuang Zhao; Cong Peng; Xiang Chen

doi:10.18632/oncotarget.11415

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma

Juan Su, Tianyuan Gao, Minghao Jiang, Lisha Wu, Weiqi Zeng, Shuang Zhao, Cong Peng and Xiang Chen _

PDF | HTML | How to cite

Oncotarget. 2016; 7:64778-64784. https://doi.org/10.18632/oncotarget.11415

Metrics: PDF 2625 views | HTML 2188 views | ?

Abstract

Juan Su1,2, Tianyuan Gao1,3, Minghao Jiang1,4, Lisha Wu5, Weiqi Zeng1,2, Shuang Zhao1,2, Cong Peng1,2 and Xiang Chen1,2

1 Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China

2 Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China

3 Department of Dermatology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi

4 Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China

5 Institute of Medical Science Research, Xiangya Hospital, Central South University, Hunan, China

Correspondence to:

Xiang Chen, email:

Cong Peng, email:

Keywords: melanoma; CD147; glycolysis; GLUT-1; PI3K/Akt pathway

Received: June 29, 2016 Accepted: August 15, 2016 Published: August 19, 2016

Abstract

Melanoma is a very malignant disease and there are still no effective treatments. CD147 participates in the carcinogenesis of multiple human cancers and GLUT-1, as a glucose transporter, is associated with tumor growth. However, the function of CD147 and GLUT-1 in melanoma have not been completely understood. Thus, in this study we investigated the expression of CD147 and GLUT-1 in melanoma tissue, which were overexpressed compared with that in nevus tissue. In addition, CD147 and GLUT-1 were co-localized in the cytoplasm of human melanoma A375 cells. Immunoprecipitation proved that CD147 interacted with GLUT-1 at D105-199. Silencing CD147 by specific siRNA could downregulate GLUT-1 level via inhibiting PI3K/Akt signaling and decrease glucose uptake in A375 cells. In vivo experiments also supported that CD147 knockdown suppressed the tumor growth in melanoma subcutaneous mice model, observed by micro PET/CT. Our results could help validate CD147 as a new therapeutic target for treating melanoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11415

Publication Alerts

Research Papers:

CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma

Abstract